Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Gain Therapeutics Inc (NASDAQ: GANX) closed at $3.86 down -2.28% from its previous closing price of $3.95. In other words, the price has decreased by -$2.28 from its previous closing price. On the day, 1.34 million shares were traded. GANX stock price reached its highest trading level at $4.1799 during the session, while it also had its lowest trading level at $3.81.
Ratios:
For a deeper understanding of Gain Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.52 and its Current Ratio is at 2.52. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In the most recent recommendation for this company, Scotiabank on March 07, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $12.
On December 06, 2024, ROTH MKM started tracking the stock assigning a Buy rating and target price of $7.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GANX now has a Market Capitalization of 148463648 and an Enterprise Value of 131134416.
Stock Price History:
The Beta on a monthly basis for GANX is 0.04, which has changed by 1.564935 over the last 52 weeks, in comparison to a change of 0.16081822 over the same period for the S&P500. Over the past 52 weeks, GANX has reached a high of $4.34, while it has fallen to a 52-week low of $1.41. The 50-Day Moving Average of the stock is 46.51%, while the 200-Day Moving Average is calculated to be 90.97%.
Shares Statistics:
For the past three months, GANX has traded an average of 1.05M shares per day and 1414110 over the past ten days. A total of 38.46M shares are outstanding, with a floating share count of 37.07M. Insiders hold about 3.62% of the company’s shares, while institutions hold 11.29% stake in the company. Shares short for GANX as of 1764288000 were 1260732 with a Short Ratio of 1.20, compared to 1761868800 on 910705. Therefore, it implies a Short% of Shares Outstanding of 1260732 and a Short% of Float of 3.3800002000000005.
Earnings Estimates
Investors are keenly observing as 4.0 analysts analyze and rate. The current performance of Gain Therapeutics Inc (GANX) in the stock market.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.13 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.63 and -$0.66 for the fiscal current year, implying an average EPS of -$0.64. EPS for the following year is -$0.71, with 4.0 analysts recommending between -$0.55 and -$0.95.
